MilliporeSigma
  • Home
  • Search Results
  • Spinal parenchymal occupation by neural stem cells after subpial delivery in adult immunodeficient rats.

Spinal parenchymal occupation by neural stem cells after subpial delivery in adult immunodeficient rats.

Stem cells translational medicine (2019-12-05)
Martin Marsala, Kota Kamizato, Takahiro Tadokoro, Michael Navarro, Stefan Juhas, Jana Juhasova, Silvia Marsala, Hana Studenovska, Vladimir Proks, Tom Hazel, Karl Johe, Manabu Kakinohana, Shawn Driscoll, Thomas Glenn, Samuel Pfaff, Joseph Ciacci
ABSTRACT

Neural precursor cells (NSCs) hold great potential to treat a variety of neurodegenerative diseases and injuries to the spinal cord. However, current delivery techniques require an invasive approach in which an injection needle is advanced into the spinal parenchyma to deliver cells of interest. As such, this approach is associated with an inherent risk of spinal injury, as well as a limited delivery of cells into multiple spinal segments. Here, we characterize the use of a novel cell delivery technique that employs single bolus cell injections into the spinal subpial space. In immunodeficient rats, two subpial injections of human NSCs were performed in the cervical and lumbar spinal cord, respectively. The survival, distribution, and phenotype of transplanted cells were assessed 6-8 months after injection. Immunofluorescence staining and mRNA sequencing analysis demonstrated a near-complete occupation of the spinal cord by injected cells, in which transplanted human NSCs (hNSCs) preferentially acquired glial phenotypes, expressing oligodendrocyte (Olig2, APC) or astrocyte (GFAP) markers. In the outermost layer of the spinal cord, injected hNSCs differentiated into glia limitans-forming astrocytes and expressed human-specific superoxide dismutase and laminin. All animals showed normal neurological function for the duration of the analysis. These data show that the subpial cell delivery technique is highly effective in populating the entire spinal cord with injected NSCs, and has a potential for clinical use in cell replacement therapies for the treatment of ALS, multiple sclerosis, or spinal cord injury.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-Laminin antibody produced in mouse, clone LAM-89, ascites fluid
Sigma-Aldrich
Anti-Glial Fibrillary Acidic Protein (GFAP)−Cy3 antibody, Mouse monoclonal, clone G-A-5, purified from hybridoma cell culture
Sigma-Aldrich
Anti-NeuN Antibody (rabbit), from rabbit, purified by affinity chromatography
Sigma-Aldrich
Anti-Vimentin Antibody, serum, Chemicon®
Sigma-Aldrich
Anti-Nestin Antibody, clone 10C2, clone 10C2, Chemicon®, from mouse
Sigma-Aldrich
Anti-Nuclei Antibody, clone 235-1, clone 235-1, Chemicon®, from mouse
Sigma-Aldrich
Anti-Olig-2 Antibody, Chemicon®, from rabbit
Sigma-Aldrich
Anti-NeuN Antibody, clone A60, clone A60, Chemicon®, from mouse
Sigma-Aldrich
Anti-NG2 Chondroitin Sulfate Proteoglycan Antibody, Chemicon®, from rabbit